We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: orth America,Central/South America,Western Europe,Eastern Europe,Australasia,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Therapeutic indications
·Furosemide is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome.
·Frusemide is particularly useful when an agent with greater diuretic potential than that of those
commonly employed is desired. Parenteral therapy should be reserved for patients unable to take
oral medication or for patients in emergency clinical situations.
· also indicated as adjunctive therapy in acute pulmonary
oedema and cerebral oedema where intense and rapid onset of diuresis is desired. If gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by the intravenous route. Parenteral use should be replaced with oral frusemide as soon as practical.
Dose and method of administration
used only in patients unable to take oral medication or in emergency situations and should be replaced with oral therapy as soon as practical
Oedema : 20 to 40mg given as a single dose, injected intramuscularly or intravenously. The intravenous dose should be given slowly .Ordinarily a prompt diuresis ensues. If needed, another dose may be administered in the same manner 2 hours later, or the dose may be increased. The dose may be raised by 20mg, and given not sooner than 2 hours after the previous dose, until the desired diuretic effect has been obtained. This individually determined single dose should then be given once or twice daily.
Acute Pulmonary Oedema : 40mg injected slowly intravenously If a satisfactory response does
not occur within 1 hour, the dose may be increased to 80mg injected slowly intravenously. If
necessary, additional therapy (e.g. digitalis, oxygen) may be administered concomitantly.
Cerebral Oedema:The following procedure is recommended, pending further experience: Intravenous injection of 20 to 40mg three times daily. A more uniform diuretic action is obtained if thesame doses are infused. The rate of infusion must be determined individually in accordance with the diuretic action and the neurological findings.
Infants and children:1mg/kg body weight and should be given slowly under close medical supervision. If the diuretic response to the initial dose is not satisfactory, dosage may be increased by 1mg/kg not sooner than 2 hours after the previous dose, until the desired effect has been obtained. Doses of greater than 6mg/kg body weight are not recommended.
Audited Supplier
Pharma Sources Insight June 2024: Globalization on the Go
